Solidus Investment

GB Soft Co., Ltd. specializes in developing non-contact measurement solutions for bio-signals, including pulse, blood pressure, oxygen saturation, and heart rate variability. These technologies facilitate basic health status checks for both daily life and medical applications. By analyzing bio-signals, GB Soft's solutions can assess fatigue, drowsiness, stress levels, and blood sugar, making them valuable across various sectors such as automotive, transportation, construction, manufacturing, and wellness. The measurement process is completed in under 10 seconds and boasts high accuracy, positioning GB Soft as a leader in this domain. The company aims to enhance daily convenience and safety through its innovative bio-signal measurement systems.

Dr.Diary is a company that specializes in developing a diabetes management application aimed at assisting users in monitoring and controlling their diabetes. Founded in 2017 and headquartered in Seoul, South Korea, the application allows users to track their blood glucose levels, record daily exercise routines, and receive reminders for medication intake. Additionally, it offers insights into how various foods affect blood sugar levels, thereby helping users make informed dietary choices. The platform includes features such as monthly health reports, daily tips for diabetes management, and communication tools that facilitate personal consultations with healthcare professionals. Through these services, Dr.Diary aims to empower individuals with diabetes to better manage their health and improve their quality of life.

Ubix Therapeutics, Inc. is a research and development company based in Seoul, South Korea, focused on the development of anti-cancer drugs utilizing a proprietary proteolysis targeting chimera platform. The company employs advanced inhibitor technology that degrades specific target proteins within cells, aiming to enhance therapeutic efficacy for various cancers. By binding to proteins associated with disease, Ubix Therapeutics seeks to provide life-saving medications for patients, thereby supporting both patients and medical professionals in the fight against cancer.

Mepsgen is a biotechnology research organization that focuses on pharmaceutical services and drug development.

Novelty Nobility Inc. is a private biotech company dedicated to researching novel angiogenesis targets and developing antibody-based therapeutics, particularly in the fields of ophthalmology and oncology. The company has identified Stem Cell Factor (SCF) and c-KIT as significant angiogenesis targets, which are linked to the proliferation and survival of hematopoietic stem cells. By focusing on the anti-SCF/c-KIT pathway, Novelty Nobility aims to address the unmet medical needs associated with existing anti-VEGF treatments, specifically regarding efficacy and long-term safety. The company is actively engaged in developing therapeutic antibodies and antibody-drug conjugates to combat drug resistance and the negative effects of aberrant blood vessel growth in conditions such as retinal diseases and solid tumors. Their lead candidate, NN2101, a full-human monoclonal antibody, is currently in preclinical development and is supported by strong patent protection in the United States and South Korea.

MicrobiotiX is a biotechnology company focused on developing innovative therapeutics that utilize bacteriophages and the microbiome to address multidrug-resistant infections and autoimmune diseases. The company's platform incorporates safe gastrointestinal microbiota transplants and formulates fecal microbiota transplant capsules for oral administration. By researching and developing effective bacteriophage therapies, MicrobiotiX aims to provide convenient and economical treatment options for patients, enhancing the healthcare sector's ability to combat challenging medical conditions.

DAAN Biotherapeutics is a biopharmaceutical company focused on developing innovative treatments for cancer patients. The company specializes in research and development in the field of cancer therapies, employing a range of approaches such as cell therapies, antibodies, and small molecule inhibitors. DAAN Biotherapeutics is particularly dedicated to immune-oncology, utilizing anticancer immune cell therapies, including natural killer (NK) cells and T cell receptors. Through its independent research infrastructure, the company conducts clinical trials to explore various treatment strategies, aiming to create effective new drugs, particularly for lung cancer. By providing healthcare providers with advanced therapeutic options, DAAN Biotherapeutics seeks to improve outcomes for cancer patients.

Kanaph Therapeutics is a biotechnology company focused on developing next-generation therapeutics for oncology and autoimmune diseases. Founded in 2019 and headquartered in Seoul, South Korea, the company engages in drug development activities ranging from discovery to early-stage clinical trials. Its therapeutic platform includes bi-specific antibodies, Fc-fusions, and small molecules. In oncology, Kanaph Therapeutics develops drugs with enhanced immuno-stimulatory activity in the tumor microenvironment for efficient tumor eradication. For autoimmune diseases, the company's pipeline features bispecific Fc-fusions that inhibit the alternative complement pathway, angiogenesis, and downstream complement activation. The company serves both Korea and the United States.

Neurophet, Inc., founded in 2016 and based in Seoul, South Korea, is a neuroscience company that specializes in developing advanced simulation software for brain stimulation effects. Their flagship product, Neurophet tES Lab, utilizes individual brain structure data and stimulus conditions to calculate and visualize these effects. The company's technology, known as Segengine, automatically segments brain magnetic resonance images into 107 regions within a minute, enhancing the precision of their neuro-navigation tools. These solutions are designed to assist clinicians in treating patients with brain diseases, including Alzheimer's, by providing detailed three-dimensional brain models and stimulation parameter guidance through deep learning and numerical optimization techniques.

Onnuri Store sells household goods, beauty, health, and food products.

Dot Mill is a mixed reality content production company.

IMBiologics is a biotechnology company focused on developing innovative immunomodulatory antibody drugs aimed at restoring physiological balance. The company specializes in creating novel treatment options for autoimmune diseases and cancer. Its offerings include antibody-based immune modulating biologics that leverage advanced mechanisms of action to modulate the immune system. By utilizing modern biotechnological techniques, IMBiologics enables new approaches to cancer treatment, positioning itself as a key player in the field of immunotherapy.

Optolane Technologies Inc. is a biotechnology company based in Seongnam, South Korea, founded in 2012. The company specializes in manufacturing portable photo sensor chip-based PCR machines for life science applications. It has developed a diagnostic platform that offers molecular and immunoassay point-of-care testing alternatives. Optolane's semiconductor-integrated in-vitro diagnostic devices focus on real-time and digital PCR, utilizing advanced optical and thermal control systems. By providing innovative diagnostic solutions, Optolane aims to facilitate disease diagnosis and enhance the quality of life for individuals.

Healthbiome is a company that researches and develops microbiome-based treatment.

GB Soft Co., Ltd. specializes in developing non-contact measurement solutions for bio-signals, including pulse, blood pressure, oxygen saturation, and heart rate variability. These technologies facilitate basic health status checks for both daily life and medical applications. By analyzing bio-signals, GB Soft's solutions can assess fatigue, drowsiness, stress levels, and blood sugar, making them valuable across various sectors such as automotive, transportation, construction, manufacturing, and wellness. The measurement process is completed in under 10 seconds and boasts high accuracy, positioning GB Soft as a leader in this domain. The company aims to enhance daily convenience and safety through its innovative bio-signal measurement systems.

M2S specializes in creating digital contents of VR and AR.

Jocoos is a tech company specializing in cloud-based video streaming solutions. Its flagship product is a platform designed for businesses to engage in live streaming, featuring advanced transcoding technology, real-time editing tools, and multimedia integration capabilities. The platform enables users to create and share engaging video content seamlessly.

Pharos iBio Co. is a company focused on the development of innovative treatments for rare and intractable diseases. Utilizing a cutting-edge drug development platform that incorporates big data and artificial intelligence, Pharos iBio aims to address significant unmet medical needs. The company’s product pipeline includes several candidate drugs, such as PHI-101-AML for refractory or relapsed acute myeloid leukemia, PHI-101-OC for platinum-resistant or refractory ovarian cancer, and PHI-101-TNBC for metastatic triple-negative breast cancer. Additionally, Pharos iBio is advancing other candidates, including PHI-201, PHI-301, and PHI-501, as part of its commitment to improving patient outcomes in challenging therapeutic areas.

Himedi, Inc. is a digital health platform based in Seoul, South Korea, that facilitates connections between international patients and medical service providers. Founded in 2011, the company offers a hospital reservation service and provides consultations with doctors, ensuring that patients receive personalized recommendations for clinics. Service managers accompany clients throughout their medical journey, enhancing the overall experience for medical tourists. Himedi aims to improve the quality of life for its users by offering comprehensive support during their treatment processes.

Market Designers is a company focused on transforming the brick-and-mortar market by leveraging online innovation to create new business opportunities. The company is developing various housing-related services, including running and cleaning, while also innovating market structures through advanced technology tailored to specific market characteristics. Their on-demand matching platform connects service providers with customers by utilizing algorithms to effectively align consumer needs with available services across sectors such as professional moving, cleaning, mortgage, and education. This approach enhances visibility for service providers and helps them expand their client base.

Orum Therapeutics, Inc. is a private biotechnology company based in Daejeon, South Korea, founded in 2016. The company specializes in the research and development of a novel class of therapeutic antibodies through its proprietary cell-penetrating antibody platform, Oromab™. This platform is designed to target cytosolic proteins, addressing unmet medical needs in cancer and rare genetic diseases. Orum's approach enables the intracellular delivery of active antibody therapeutics or payloads, allowing it to inhibit drug targets that are typically considered undruggable by existing small molecules or antibody treatments. The technology is adaptable, capable of targeting various cell types and intracellular proteins without the need for chemical modifications. By merging the precision of antibodies with the efficacy of protein degraders, Orum aims to facilitate the development of new medicines that can effectively treat patients with challenging health conditions.

MOTIV Intelligence is an ad-tech company that focuses on automating the marketing process. The company utilizes user behavioral data collected from mobile devices to deliver personalized advertisements to individuals who visit websites but do not complete a purchase. By leveraging this data, MOTIV Intelligence aims to enhance marketing effectiveness and improve conversion rates for businesses.

Orum Therapeutics, Inc. is a private biotechnology company based in Daejeon, South Korea, founded in 2016. The company specializes in the research and development of a novel class of therapeutic antibodies through its proprietary cell-penetrating antibody platform, Oromab™. This platform is designed to target cytosolic proteins, addressing unmet medical needs in cancer and rare genetic diseases. Orum's approach enables the intracellular delivery of active antibody therapeutics or payloads, allowing it to inhibit drug targets that are typically considered undruggable by existing small molecules or antibody treatments. The technology is adaptable, capable of targeting various cell types and intracellular proteins without the need for chemical modifications. By merging the precision of antibodies with the efficacy of protein degraders, Orum aims to facilitate the development of new medicines that can effectively treat patients with challenging health conditions.

essys is a Manufacturing and sales of automotive IT parts.

Anygen Co., Ltd., established in 2000, is a South Korean bio-venture company specializing in the manufacture of peptide Active Pharmaceutical Ingredients (APIs) and drug development. The company produces a range of peptides, including GMP, generic, custom, and catalog varieties, and offers related services. Anygen is also engaged in the development of novel drugs, such as AGM-130 for breast cancer, AGM-212 for type 2 diabetes, AGM-251 for neuropathic pain, and AGM-290 for MRSA infection treatment. Headquartered in Gwangju, Anygen is the first bio-venture company in the Gwangju and Jeonnam province, and it aims to expand globally. The company supplies high-quality peptide medicinal materials, approved by GMP, at competitive prices, contributing to the stability of the peptide drug raw materials market and promoting public health.

Techcross is a manufacturer of ballast water management systems focused on protecting the marine environment. The company develops innovative systems that employ electrolysis technologies to prevent the pollution of ship ballast water from large vessels, including tankers and container ships. By enabling the treatment of invasive marine species contained in ballast water, Techcross plays a crucial role in promoting sustainable maritime practices across various countries.

Purunagun Distribution is a Manufacture and distribution of ice cream with domestic agricultural products.

Cheongwoo Food is a Comprehensive Confectionery.

Vitrosys Inc. is a bio-engineering company based in Yeongju, South Korea, founded in 2002. The company specializes in the development and manufacturing of plant-based medicines, utilizing advanced biotechnological methods to create products from single cells and tissues. Vitrosys offers a diverse range of health-related products, including natural materials, bio reactors, and functional foods designed to promote health. Its product line features cultured roots of Korean mountain ginseng and various extracts, vials, and beverages derived from these roots. Additionally, Vitrosys provides research outsourcing and joint research services, aimed at supporting the industrialization of beneficial plant resources in strictly controlled facilities. The company's commitment to biopharmaceutical innovation enables the extraction and identification of natural metabolites with physiological benefits for human health.

Genomictree, Inc. is a molecular diagnostics company focused on epigenomic biomarker-based technologies. The company develops innovative solutions aimed at addressing unmet needs within the healthcare market. By leveraging advancements in molecular diagnostics, Genomictree strives to enhance disease detection and management, ultimately improving patient outcomes.

Alteogen Inc. is a biotechnology company founded in 2008 and headquartered in Daejeon, South Korea. The company specializes in the development of next-generation biopharmaceuticals, including long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars. Alteogen's innovative technologies include NexP Fusion Technology for long-acting biobetters and NexMab ADC Technology for antibody-drug conjugates. Its current pipeline features several candidates in various stages of clinical trials, such as ALT-P1, a long-acting human growth hormone in Phase IIa, and ALT-Q2, a long-acting coagulation factor VII for hemophilia. Additionally, the company is developing ALT-P7 for targeted breast and gastric cancer and ALT-Q5, an antibody-drug conjugate for ovarian cancer. Alteogen also collaborates with other pharmaceutical companies, including Kissei Pharmaceutical and Cristalia, to enhance its product offerings.

Novarex Co., Ltd., founded in 2008 and headquartered in Cheongju, South Korea, specializes in the development and production of health functional foods and raw materials. The company offers a diverse range of dietary supplements, including lactic acid bacteria, probiotics, omega-3 products, and vitamins and minerals. Novarex provides various formulations such as tablets, hard capsules, powders, gummy jellies, and stick jellies, catering to different health needs, including eye health, dietary management, and support for pregnant women and children. Formerly known as Health Science Co., Ltd., Novarex rebranded in November 2011 to reflect its commitment to health and nutrition on both domestic and international markets.

IDAL SYSTEM is a Smart RPC Management System.

Kookdae F & B is a franchise business.

BioLeaders Corporation is a healthcare company based in Yongin, South Korea, founded in 1999. The company focuses on developing innovative medicines, particularly in the field of oncology, with its flagship product being P53, an anti-cancer drug. BioLeaders is advancing several pipeline products, including BLS-H01, currently in phase 3 clinical trials for cervical cancer, and BLS-M07, which has completed phase 2b trials for the same condition. Additionally, the company is working on BLS-M22 for the treatment of Duchenne muscular dystrophy and BLC-H03, a vaccine adjuvant. Beyond pharmaceuticals, BioLeaders also offers health functional foods, raw materials, and functional cosmetic ingredients, positioning itself as a comprehensive provider in the healthcare sector.

Maniker F&G Co., Ltd. is a South Korean company specializing in the production, processing, and sale of frozen, chilled, and retorted food products. Founded in 1993 and headquartered in Yongin, the company offers a diverse range of meat products, including chicken and beef items, aimed at both home and business consumers. Notable offerings include Ginseng chicken stew, Mung bean chicken stew, Premium Samgyetang, boneless chicken tender, and Maniker popcorn chicken. Maniker F&G is also involved in exporting its products to the United States, emphasizing a commitment to providing delicious and safe food options through advanced meat processing technology and continuous innovation.